Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues.
Hum Vaccin Immunother
; 18(1): 1917237, 2022 12 31.
Article
em En
| MEDLINE
| ID: mdl-33908816
ABSTRACT
This communication seeks to address the questions and criticisms issued by Gomez and colleagues in their letter on our original study "Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants." Gomez and colleagues are concerned that the assumptions used in our model may have unintended negative impacts for Brazil decision-making and we intend to clarify any potential misinterpretation of our assessment.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções Pneumocócicas
Tipo de estudo:
Prognostic_studies
Limite:
Humans
/
Infant
País/Região como assunto:
America do sul
/
Brasil
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article